---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-105029"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:38:25.535202+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q2 net loss narrows to $7.0M; cash burn slows; ATH-1105 Phase 1 data support ALS development

## Summary
- Net loss of $7.0M ($0.18/sh) vs $26.9M ($0.70) in Q2 2024, driven by lower R&D and G&A spend.
- Cash, equivalents and investments $29.8M as of June 30, 2025, down from $51.3M at Dec 31, 2024.
- R&D expenses fell to $3.7M from $22.2M; G&A to $3.6M from $5.9M, reflecting cost reduction after LIFT-AD failure.
- Phase 1 trial of ATH-1105 (ALS) showed favorable safety, dose-proportional PK, and CNS penetration; preparation for future ALS trial ongoing.
- Company continues to explore strategic alternatives with Cantor Fitzgerald; fosgonimeton development paused.

## SEC filing metadata
- accession: 0000950170-25-105029
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017025105029/0000950170-25-105029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017025105029/atha-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-105029
- JSON: https://secwatch.observer/filing/0000950170-25-105029.json
- Plain text: https://secwatch.observer/filing/0000950170-25-105029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.